Non-Small Cell Carcinoma

A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC)

PMID 34994615 · Pruis et al., 2021 · Open in CIViC

A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC)

PMID 26709483 · Lee et al., 2015 · Open in CIViC

38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC)

PMID 37041472 · Hu et al., 2023 · Open in CIViC

A 67-year old Asian female (non-smoker) diagnosed with stage IV metastatic lung adenocarcinoma and also presented with superior vena cava syndrome and weight loss. Ultrasound-guided biopsy of lymph no… (full text at CIViC)

PMID 27666659 · Ou et al., 2017 · Open in CIViC

A 71-year old male (non-smoker) was diagnosed with stage IV lung adenocarcinoma. Genomic profiling of a lung cavity showed MET exon 14 skipping mutation and the patient began crizotinib therapy. Treat… (full text at CIViC)

PMID 28629543 · Schrock et al., 2017 · Open in CIViC

Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC)

PMID 15735036 · Ma et al., 2005 · Open in CIViC

A 69-year old male (50 year history of smoking) was diagnosed with stage IIIC lung adenocarcinoma after a 13.2 x 8.8 x 9 cm mass with multiple lymph node metastases were found in a CT scan. Next-gener… (full text at CIViC)

PMID 29381967 · Tan et al., 2017 · Open in CIViC

A 72-year old man (non-smoker) was diagnosed with lung adenocarcinoma and developed multiple recurring brain and lung metastases. Systemic chemotherapy was administered, and genomic analysis of the su… (full text at CIViC)

PMID 34695875 · Kunimasa et al., 2021 · Open in CIViC

A 83-year old woman presented with sarcomatoid squamous cell carcinoma. Next-generation sequencing revealed a MET exon 14 skipping mutation (c.3028+3A>G) and the patient was treated with crizotinib (2… (full text at CIViC)

PMID 36147925 · Sun et al., 2022 · Open in CIViC

In one patient with metastastic lung adenocarcinoma harboring a c-Cbl binding site alteration (Y1021H) deomonstrated radiological response to crizotinib and a PFS of 10.6 months.

PMID 31809977 · Wiesweg et al., 2020 · Open in CIViC

A 61-year old female (non-smoker) was diagnosed with stage IIIb adenocarcinoma of the left lung. Next-generation sequencing of the peripheral blood revealed MET Y1003S mutation. The patient was treate… (full text at CIViC)

PMID 30885356 · Miao et al., 2019 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR. There was a significant association between MIR21 expression and platinum sensitivity (p=0.007). MIR21 expression was signif… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR and a significant association between MIR21 expression and platinum sensitivity was found (p=0.007). To directly test the rol… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

In a retrospective cohort of metastatic lung adenocarcinoma from the BATTLE-2 trial (n = 72), patients with CDKN2A and MTAP co-underexpression tumors (n = 26; representative for 9p21 loss) demonstrate… (full text at CIViC)

PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC

In a cohort of 178 patients with lung squamous cell carcinoma from The Cancer Genome Atlas, high neoantigen burden was significantly associated with improved disease-free survival compared with low ne… (full text at CIViC)

PMID 30824826 · Chae et al., 2019 · Open in CIViC

Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations… (full text at CIViC)

PMID 29127119 · Hayashi et al., 2018 · Open in CIViC

In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD).

Open in CIViC

In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7）and disease control rate was … (full text at CIViC)

Open in CIViC

In a retrospective study of stage IV NSCLC patients treated with first-line platinum doublet chemotherapy (n = 103; 51 KEAP1/NFE2L2/CUL3-mutant, 52 WT), mutations in NFE2L2, KEAP1, or CUL3 were associ… (full text at CIViC)

PMID 31548347 · Jeong et al., 2020 · Open in CIViC

NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context.

PMID 20007775 · Westhoff et al., 2009 · Open in CIViC

A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC)

PMID 27693535 · Klempner et al., 2017 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK T1151M co-mutation, demonstrated resistance to crizotinib treatment (IC50: 346.65… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In an in vitro study, a PC-9 cell line expressing NRAS Q61K mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing NRAS wild-type. Sensitivity was determi… (full text at CIViC)

PMID 22773810 · Ohashi et al., 2012 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, t… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In this study, an NRG1 overexpressing PC9HRG cell line was resistant to erlotinib because of active HER3 signalling. Treatment with afatinib was effective in disrupting signaling and cell line viabili… (full text at CIViC)

PMID 26418897 · Yonesaka et al., 2015 · Open in CIViC

In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decrea… (full text at CIViC)

PMID 23390248 · Hegde et al., 2013 · Open in CIViC

A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.

PMID 30624546 · Hong et al., 2019 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

25 tumors from individuals with lung adca who have <= 10 pack-year smoking history underwent whole exome sequencing and RNA-seq. 5 tumors did not identify an established oncogenic driver. In one (tumo… (full text at CIViC)

PMID 35247929 · Hunihan et al., 2022 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.

PMID 26745678 · Li et al., 2016 · Open in CIViC

Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H… (full text at CIViC)

PMID 19755855 · Ramos et al., 2009 · Open in CIViC

In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression … (full text at CIViC)

PMID 19366796 · McDermott et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC)

PMID 19513541 · Zou et al., 2009 · Open in CIViC

HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM). The presence of p1… (full text at CIViC)

PMID 16906227 · Engelman et al., 2006 · Open in CIViC

48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed… (full text at CIViC)

PMID 27304188 · Belchis et al., 2016 · Open in CIViC